Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Beijing Chao Yang Hospital |
---|---|
Information provided by: | Beijing Chao Yang Hospital |
ClinicalTrials.gov Identifier: | NCT00781716 |
This study is to compare the clinical effect of CYPHER® stent and ENDEAVOR® stent in patients with acute ST elevation myocardial infarction. It also aims to analyze the current status of emergency PCI green channel (time taken from door→ hospital→ PIC sign-off→ needle→ balloon) for patients with ST elevation myocardial infarction in China.
Condition | Intervention |
---|---|
Myocardial Infarction Coronary Artery Disease |
Device: Drug eluting coronary stent system |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Comparison of Safety and Efficacy of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction and Analysis of Current Status of Emergency PCI Green Channel for Patients With ST Elevation Myocardial Infarction in China |
Estimated Enrollment: | 1020 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | May 2011 |
Estimated Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cypher Stent: Active Comparator
Cypher Sirolimus-Eluting Coronary Stent System
|
Device: Drug eluting coronary stent system
Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
|
Endeavor Stent: Active Comparator
Endeavor Zotarolimus-Eluting Coronary Stent System
|
Device: Drug eluting coronary stent system
Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
|
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: LeFeng Wang, MD | 86-13601255020 | CrestMI@gmail.com |
Contact: Caihong Wang | 86-13001980897 | crest_mi@sina.com |
China, BJ | |
Beijing Chaoyang Hospital Heart Center | |
Beijing, BJ, China, 10000 |
Principal Investigator: | LeFeng Wang, MD | Chaoyang Hospital |
Responsible Party: | Beijing Chao Yang Hospital Heart Center ( Dr. LeFeng Wang/Director of the Cath Lab ) |
Study ID Numbers: | Version 1.0-Sep 10, 2008 |
Study First Received: | October 28, 2008 |
Last Updated: | October 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00781716 |
Health Authority: | China: State Food and Drug Administration |
ST elevation myocardial infarction Drug eluting stents |
Arterial Occlusive Diseases Sirolimus Heart Diseases Clotrimazole Miconazole Myocardial Ischemia Tioconazole Vascular Diseases |
Ischemia Arteriosclerosis Coronary Disease Necrosis Emergencies Infarction Myocardial Infarction Coronary Artery Disease |
Anti-Bacterial Agents Anti-Infective Agents Pathologic Processes Immunologic Factors Antineoplastic Agents Antifungal Agents |
Therapeutic Uses Physiological Effects of Drugs Cardiovascular Diseases Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |